MX2011013666A - Compuestos heterociclicos y sus usos. - Google Patents

Compuestos heterociclicos y sus usos.

Info

Publication number
MX2011013666A
MX2011013666A MX2011013666A MX2011013666A MX2011013666A MX 2011013666 A MX2011013666 A MX 2011013666A MX 2011013666 A MX2011013666 A MX 2011013666A MX 2011013666 A MX2011013666 A MX 2011013666A MX 2011013666 A MX2011013666 A MX 2011013666A
Authority
MX
Mexico
Prior art keywords
inflammatory
disorders
myelo
restricted
diseases
Prior art date
Application number
MX2011013666A
Other languages
English (en)
Inventor
Michael G Johnson
Timothy D Cushing
Felix Gonzalez Lopez De Turiso
Vatee Pattaropong
Todd J Kohn
Paul John Dransfield
Jillian L Simard
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2011013666A publication Critical patent/MX2011013666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Se describen heteroarilos bicíclicos sustituidos y composiciones que los contienen, para el tratamiento de inflamación general, artritis, enfermedades reumáticas, osteoartritis, enfermedades inflamatorias del intestino, trastornos inflamatorios de los ojos, trastornos de vejiga inflamatoria o inestable, psoriasis, dolencias de la piel con componentes inflamatorios, afecciones inflamatorias crónicas, incluyendo pero no restringido a enfermedades autoinmunitarias tales como lupus eritematoso sistémico (SLE), miastenia gravis, artritis reumatoide, encefalomielitis diseminada aguda, púrpura trombocitopénica idiopática, esclerosis múltiple, síndrome de Sjoegren y anemia hemolítica autoinmunitaria, afecciones alérgicas incluyendo todas las formas de hipersensibilidad. La presente invención también abarca métodos para tratar cánceres que están mediados, dependen de o están asociados con la actividad de p110d incluyendo pero no restringido a leucemias, tal como Leucemia mieloide aguda (AML), Síndrome mielo-displástico (MDS) , enfermedades mielo-proliferativas (MPD), Leucemia Mieloide Crónica (CML), leucemia linfoblástica aguda de célula T (T-ALL), leucemia linfoblástica aguda de célula B (B-ALL), linfoma no de Hodgkins (NHL), linfoma de célula B y tumores sólidos, tal como cáncer de mama.
MX2011013666A 2009-06-25 2010-06-25 Compuestos heterociclicos y sus usos. MX2011013666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22025909P 2009-06-25 2009-06-25
PCT/US2010/040027 WO2010151791A1 (en) 2009-06-25 2010-06-25 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
MX2011013666A true MX2011013666A (es) 2012-03-06

Family

ID=42776992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013666A MX2011013666A (es) 2009-06-25 2010-06-25 Compuestos heterociclicos y sus usos.

Country Status (18)

Country Link
US (1) US8940724B2 (es)
EP (1) EP2445886B1 (es)
JP (1) JP2012531438A (es)
KR (1) KR20140015121A (es)
CN (1) CN102625799A (es)
AR (1) AR077254A1 (es)
AU (1) AU2010265932B2 (es)
BR (1) BR112012000660A2 (es)
CA (1) CA2765823A1 (es)
CL (1) CL2011003297A1 (es)
EA (1) EA201270051A1 (es)
IL (1) IL216973A0 (es)
MX (1) MX2011013666A (es)
SG (1) SG176978A1 (es)
TW (1) TW201111376A (es)
UY (1) UY32742A (es)
WO (1) WO2010151791A1 (es)
ZA (1) ZA201200613B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
JP5712524B2 (ja) * 2009-10-28 2015-05-07 Jsr株式会社 液晶配向剤および液晶表示素子
WO2011054433A1 (en) * 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
CN103097381B (zh) * 2010-02-22 2015-10-07 默克专利有限公司 作为激酶抑制剂的1,8-萘啶物质
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
FR2961206B1 (fr) * 2010-06-09 2012-07-20 Rhodia Operations Procede de preparation de composes esteramides
AU2011271462A1 (en) * 2010-06-30 2013-01-10 Amgen Inc. Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors
AU2011272862A1 (en) * 2010-06-30 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
US9527805B2 (en) 2010-09-10 2016-12-27 Robert A. Casero Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
KR20130016041A (ko) 2011-08-04 2013-02-14 재단법인 의약바이오컨버젼스연구단 신규한 아닐린 유도체 및 이의 용도
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
WO2014015936A1 (en) * 2012-07-23 2014-01-30 Merck Patent Gmbh Ligands and their preparation
CN104870017B (zh) 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
EP2950649B1 (en) 2013-02-01 2020-03-04 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
MX362896B (es) 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
DK3068393T5 (da) 2013-11-11 2022-08-22 Amgen Inc Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer
AU2015276537B2 (en) * 2014-06-16 2019-03-14 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
MA40250A (fr) 2014-07-04 2017-05-10 Lupin Ltd Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
CN106008479B (zh) * 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
US10667517B2 (en) 2015-08-07 2020-06-02 Bayer Cropscience Aktiengesellschaft 2-(Het)aryl-substituted fused heterocycle derivatives as pesticides
AU2016333987A1 (en) 2015-10-05 2018-05-10 Ny State Psychiatric Institute Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US10544113B2 (en) 2016-03-07 2020-01-28 National Health Research Institute Thiazolidinone compounds and use thereof
GB201604969D0 (en) * 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
MX2019013862A (es) 2017-05-23 2020-01-20 Mei Pharma Inc Terapia de combinacion.
CA3072476A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. Combination therapy
IL272909B2 (en) 2017-09-07 2024-01-01 Univ Res Inst Inc Augusta A specific AKT3 activator and its uses
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
SG11202112855WA (en) 2019-05-21 2021-12-30 Amgen Inc Solid state forms
WO2021076655A1 (en) 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
CN110963967B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种2-甲基-4-氨基喹啉的制备方法
CN111018777B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种地喹氯铵的制备方法
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
CN117157284A (zh) * 2021-03-18 2023-12-01 苏州国匡医药科技有限公司 Ctla-4小分子降解剂及其应用
CN113277978B (zh) * 2021-06-02 2022-06-03 河南师范大学 一种2，4-双取代喹啉类化合物的制备方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823147A (en) * 1968-05-24 1974-07-09 Hoechst Ag Thiophenyl-substituted quinophthalone dispersion dyestuffs
BR6908932D0 (pt) * 1968-05-24 1973-01-02 Hoechst Ag Processo para a preparacao de corantes de dispersao da serie da quinoftalona
DE2025288A1 (de) * 1970-05-23 1971-12-09 Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt Dispersionsfarbstoffe der Chinophthalonreihe und Verfahren zu deren Herstellung
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5430153A (en) 1991-04-03 1995-07-04 Korea Research Institute Of Chemical Technology 2-quinolinone derivatives
EP0527051B1 (en) * 1991-08-06 2000-03-22 Mitsui Chemicals, Inc. Quinophthalone dyes, ink composition and transfer sheet containing them
JP3347779B2 (ja) * 1991-11-14 2002-11-20 大日本印刷株式会社 熱転写シート
GB9312891D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
AU3088799A (en) * 1998-03-18 1999-10-11 Humanetics Corporation Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
DE60009888T2 (de) * 1999-04-21 2005-04-21 Wyeth Corp Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
US6355636B1 (en) * 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
HUP0300547A2 (hu) 2000-03-13 2003-07-28 American Cyanamid Co. Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására
WO2004069250A1 (en) 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004108704A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyrimidin-4-yl 3-cyanoquinoline derivatives for use in the treatment of tumours
WO2004108703A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinyl 3-cyanoquinoline derivatives for use in the treatment of tumours
EP1633718B1 (en) 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
CA2599992A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CA2608540A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
ES2446417T3 (es) * 2007-03-23 2014-03-07 Amgen Inc. Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K)
GB0821693D0 (en) 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
AR077254A1 (es) 2011-08-10
AU2010265932A1 (en) 2012-01-19
SG176978A1 (en) 2012-02-28
AU2010265932B2 (en) 2014-11-20
ZA201200613B (en) 2012-10-31
UY32742A (es) 2010-12-31
EA201270051A1 (ru) 2012-05-30
BR112012000660A2 (pt) 2016-11-16
CL2011003297A1 (es) 2012-06-15
CN102625799A (zh) 2012-08-01
US8940724B2 (en) 2015-01-27
EP2445886B1 (en) 2016-03-30
IL216973A0 (en) 2012-02-29
JP2012531438A (ja) 2012-12-10
TW201111376A (en) 2011-04-01
CA2765823A1 (en) 2010-12-29
KR20140015121A (ko) 2014-02-06
US20100331293A1 (en) 2010-12-30
WO2010151791A1 (en) 2010-12-29
EP2445886A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
MX2011013666A (es) Compuestos heterociclicos y sus usos.
TN2012000449A1 (en) Heterocyclic compounds and their uses
MX2013007261A (es) Compuestos heterociclicos y sus usos.
MX2009009968A (es) Compuestos heterociclicos y sus usos.
MX2011013667A (es) Compuestos heterociclicos y sus usos.
MX2012015135A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2011013510A (es) Compuestos heterociclicos y sus usos.
MX2009009913A (es) Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
MX2012015134A (es) Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
MX2011013901A (es) Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
MX2012015143A (es) Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
MX2009010050A (es) Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
MX2012015147A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
PH12014502246A1 (en) Heterocyclic compounds and their uses
MX2023000100A (es) Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma.
MX368214B (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
MX2018011046A (es) Composiciones y metodos para tratar canceres.
CY1117196T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
AR090705A1 (es) Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
MX2016009624A (es) Compuestos heterobiciclicos novedosos como agonistas del opioide kappa.
CY1114775T1 (el) Παραγωγα 3-υποκατεστημενης κινολινης ή κινοξαλινης και η χρηση τους ως αναστολεων της 3-κινασης φωσφατιδυλινοσιτολης (ρι3κ)
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.
UY34748A (es) Compuestos heterocíclicos y sus usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal